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Available online 28 October 2017Duchenne muscular dystrophy (DMD) is caused by abnormalities in the dystrophin gene and is clinically
characterised by childhood muscle degeneration and cardiomyopathy. We produced an induced pluripotent
stem cell line from a DMD patient's dermal ﬁbroblasts by electroporation with episomal vectors containing:
hL-MYC, hLIN28, hSOX2, hKLF4, hOCT3/4. The resultant DMD iPSC line (CCMi001DMD-A-3) displayed iPSCmor-
phology, expressed pluripotency markers, possessed trilineage differentiation potential and was karyotypically
normal. MLPA analyses performed on DNA extracted from CCMi001DMD-A-3 showed a deletion of exons 49
and 50 (CCMi001DMD-A-3, Δ49, Δ50).
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Resource TableRegenerative Medicine, Centro
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. This is an open access article under1. Resource utility
This tool is valuable for the identiﬁcation of novel DMD pathophys-
iological mechanisms downstream of dystrophin mutations and for
screening putative therapies.
2. Resource details
Duchennemuscular dystrophy (DMD) is a severe early onset form of
muscular dystrophy (MD) caused by either spontaneous mutations orthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
129G. Spaltro et al. / Stem Cell Research 25 (2017) 128–131inherited nonsense point mutations in the dystrophin gene (Flanigan
2012). Mutations in the dystrophin gene result in the failed expression
of full-length dystrophin protein. Dystrophin deﬁciency is associated
with skeletalmuscle damage and impaired regeneration, and cardiomy-
opathy. Following institutional ethical committee approval and patient
informed consent, dermal ﬁbroblasts were isolated by explant culture
of a skin biopsy obtained from a 34-year-oldmale with DMD. To protect
privacy, no identifying patient information is included in this publica-
tion. The patient presented with an incidental ﬁnding of hyperkalaemia
at 18months of age. Loss of ambulation occurred at 10 years of age. TheA B
C
E
Fig. 1. Derivation of the Duchenne muscular dystrophy induced pluripotent stem cell line
CCMi001DMD-A-3,Δ49,Δ50 was conﬁrmed by immunoﬂuorescence staining. B FACS analysis
line expressed the pluripotency marker SSEA4 as indicated above by the summary data histogr
values are mean± SEM, Student’s t test, n=3). C An in vitro trilineage differentiation assay rev
layers. D Representative karyogram from CCMi001DMD-A-3, Δ49, Δ50 showing a normal 46,
ampliﬁcation assay (MLPA) revealed a normal DMD genotype of Control iPSCs (lower electro
derived from Control iPSCs (ﬁlled arrow, lane 1, inset); CCMi001DMD-A-3, Δ49, Δ50 contain
DMDmutation caused a lack of the full-length dystrophin protein expression (open arrow, lanexplanted patient ﬁbroblasts were reprogrammed into induced pluripo-
tent stem cells (iPSCs) by electroporation with plasmids encoding
humanL-MYC, LIN28, SOX2, KLF4, OCT3/4 (Okita et al. 2007) and cultured
under feeder-free deﬁned conditions. After 31 days of reprogramming,
iPSC colonies were manually selected and culture expanded. The iPSC
line described in this publication was named CCMi001DMD-A-3, and en-
tered iPSC characterisation by evaluating: distinctive iPSC-likemorpholo-
gy and expression of the pluripotencymarkers by immunocytochemistry
and FACS analyses (SSEA4, Sox2, Nanog and Oct4, Fig. 1A, 84% SSEA4+
cells Fig. 1B); potential to differentiate along ectodermal, mesodermalD
CCMi001DMD-A-3, Δ49, Δ50. A Expression of several pluripotency-associated markers in
revealed that large percentages of cells in CCMi001DMD-A-3, Δ49, Δ50 and a Control iPSC
am and a representative FACS analysis histogram (Control v CCMi001DMD-A-3, Δ49, Δ50,
ealed that CCMi001DMD-A-3,Δ49, Δ50 was capable of differentiation into all three germ
XY karyotype without any measurable anomalies. EMultiplex ligation-dependent probe
pherograms) with normal full-length dystrophin protein expression in cardiomyocytes
ed deletions of DMD exons 49 and 50 (upper right electropherogram) this out-of-frame
e 2, inset) in cardiomyocytes derived from CCMi001DMD-A-3, Δ49, Δ50.
130 G. Spaltro et al. / Stem Cell Research 25 (2017) 128–131and endodermal lineages (Nestin, αSMA and Sox17, Fig. 1C). Cytogenetic
analysis was conducted on 30 mitosis from two independent cultures.
The CCMi001DMD-A-3, iPSC line was karyotypically normal (size,
shape, and number of chromosomes) at P23 (Fig. 1D). To detect the
speciﬁc dystrophin mutation present in the CCMi001DMD-A-3 iPSC
line, multiple ligation probe ampliﬁcation (MLPA) analyses was
performed on DNA extracted from CCMi001DMD-A-3 and a control
iPSC line (derived from a healthy control subject's dermal ﬁbroblasts).
CCMi001DMD-A-3, showed a deletion of exons 49 and 50
(CCMi001DMD-A-3, Δ49, Δ50; Fig. 1E). Disruption of the DMD reading
framewas conﬁrmed bymeasuring the expression of dystrophin protein
in functional CMs derived from CCMi001DMD-A-3, Δ49, Δ50 (DMD-A-
3-CMs) bywestern blot and comparing it to CMs derived from iPSCs ob-
tained from a healthy control subject's dermal ﬁbroblasts (Control-CMs;
Fig. 1E inset). DMD-A-3-CMs did not display full-length dystrophin pro-
tein expression (Fig. 1E inset, lane 2) which was observed at 427 kDa in
Control-CMs (Fig. 1E inset, lane 1).3. Materials and methods
3.1. Reprogramming of DMD patient's ﬁbroblasts to iPSCs
All investigations were conducted according to the principles stated
in the Declaration of Helsinki. Following informed consent under the
regulations of the local ethics committee (European Institute of Oncolo-
gy and Centro Cardiologico Monzino, Italy) the patient's ﬁbroblasts
were isolated from a skin biopsy by explant culture. Fibroblasts were
transfected with episomal vectors (pCXLE-hUL, pCXLE-hSK, pCXLE-
hOCT3/4; Addgene) by electroporation (Neon™ transfection system,
Invitrogen), transferred into a single well of a 6 well plate pre-coated
with human recombinant vitronectin (Life Technologies) and cultured
at 37 °C with 5% CO2. On day 3 post transfection transfected ﬁbroblast
media was replaced with reprogramming media (ReproTeSR™,
Stemcell Technologies) which was changed every day. Colonies were
harvested when they reached 1000 μm in diameter bymanual isolation
using a 25 gauge sterile syringe and transferred into an individual well
of a 12-well plate containing mTeSR1™media (Stemcell Technologies)
supplemented with RevitaCell™ (Life Technologies). iPSCs were main-
tained in mTeSR1™ media with daily media changes. At 80–90%
conﬂuency, iPSCs were non-enzymatically passaged (every 3–4 days)
with ReLeSR™ (Stemcell Technologies) and replated as small aggre-
gates in mTeSR1™media containing RevitaCell™. Stock vials of iPSCsTable 1
CCMi001DMD-A-3, Δ49, Δ50 summary information and, chracterisation and quality control an
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germlaye
Donor screening (OPTIONAL) Not performed –
Genotype additional info (OPTIONAL) Not performed –
Not performed –were harvested in mFreSR™ (Stemcell Technologies) and stored at
−180 °C for future experiments (Table 1).
3.2. Pluripotency marker immunocytochemistry
CCMi001DMD-A-3, Δ49, Δ50 iPSCs were cultured until conﬂuent,
split and transferred to vitronectin-coated chamber slides for analysis
of pluripotency proteins. iPSCs were analysed with a confocal micro-
scope (LSM710, Zeiss). All antibody details are listed in Table 2.
3.3. Flow cytometry
CCMi001DMD-A-3, Δ49, Δ50 were dissociated using Gentle Cell
Dissociation Reagent (Stemcell Technologies). Non-speciﬁc staining
was blocked using 5% Bovine Serum Albumin (BSA; Sigma-Aldrich)
in PBS (Lonza). Cells were stained with a SSEA4 (1:100, 1 h; ab16287
Abcam) per reaction followed by goat anti-mouse IgM-FITC (1:200, 1 h;
A11659 Life Technologies). Cells were analysed using a FACSCalibur™
ﬂow cytometer (BD Biosciences).
3.4. In vitro trilineage differentiation potential assay
CCMi001DMD-A-3, Δ49, Δ50 iPSCs were subjected to monolayer
differentiation using the STEMdiff™ trilineage differentiation kit
(Stemcell Technologies) according to the manufacturer's instructions.
On day 5 mesodermal- and endodermal-induced cells were ﬁxed (4%
formaldehyde, 3 min at RT) and permeabilised (0.5% triton, 3 min at
RT). Unspeciﬁc binding was blocked in 3% BSA (2 h RT) and expression
of αSMA and Sox17 were evaluated. Following 7 days of ectodermal-
induction, cells wereﬁxed, permeabilized and blocked as before and ex-
pression of Nestin was evaluated. Differentiated cells were analysed by
confocal microscopy (LSM710, Zeiss). All antibody details are listed in
Table 2.
3.5. Karyotyping
Metaphase chromosomes were prepared from CCMi001DMD-A-3,
Δ49, Δ50 cultures at passage 23 (P23). After 48–96 h colcemid (10
μg/ml) was added for 3 h at 37 °C. iPSCs were incubated in hypotonic
solution (Sodium Citrate 0.6%, KCl 0.13%) at RT for 10 min, washed
with Ibraimov solution (acetic acid 5%), ﬁxed in Optichrome (28 °C,
42% rH) with methanol/acetic acid (3:1), Q-banded and photographed.
Karyotype images were obtained at 100× magniﬁcation (Olympus BXalyses.
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Table 2
RRID Requirement for antibodies: use http://antibodyregistry.org/ to retrieve RRID for antibodies and include ID in table as shown in examples.
Antibodies used for immunocytochemistry/ﬂow-cytometry
Antibody Dilution Company Cat# and RRID
Pluripotency markers Mouse anti-SSEA4 1:200 (for SSEA4 IF) Abcam Cat# ab16287, RRID:AB_778073;
Rabbit anti-Nanog 1:100 (for FACS) Abcam Cat# ab21624, RRID:AB_446437;
Rabbit anti-Sox2 1:100 Abcam Cat# ab97959, RRID:AB_2341193;
Rabbit anti-Oct4 1:200 Abcam Cat# ab19857, RRID:AB_445175
Differentiation markers Mouse anti-Nestin 1:300 Stemcell Technologies Cat# 60091AD, RRID:AB_2650581;
Rabbit anti-Sox17 1:300 Cell Signaling Inc. Cat# 81778, RRID:AB_2650582;
Mouse anti-αSMA 1:100 Millipore Cat# CBL171, RRID:AB_2223166
Western immunoblot Rabbit anti-Dystrophin 1:500 Abcam Cat# ab15277, RRID:AB_301813;
Mouse anti-Gapdh 1:2000 Santa Cruz Technologies Cat# sc-25778, RRID:AB_10167668
Secondary antibodies Anti-Mouse IgG, Alexa®Fluor 488 1:400 (for SSEA4 IF)
1:200 (for SSEA4 FACS)
Thermo Fisher Scientiﬁc Cat# A11059, RRID:AB_2534106
Anti-Rabbit IgG, Alexa®Fluor 488 1:200 (for Nanog)
1:400 (for Sox2/Oct4)
1:500 (for Sox17)
Thermo Fisher Scientiﬁc Cat# A11034, RRID:AB_2576217
Anti-Mouse IgG2a Cross-Adsorbed Secondary
Antibody, Alexa®Fluor 633
1:400 (for αSMA) Thermo Fisher Scientiﬁc Cat# A-21136, RRID:AB_2535775
Anti-rabbit IgG, HRP 1:1000 GE Healthcare Cat# NA 9340V, RRID:AB_772206
Anti-Mouse IgG, HRP 1:10,000 GE Healthcare Cat# NA9310-1ml, RRID:AB_772193
131G. Spaltro et al. / Stem Cell Research 25 (2017) 128–131microscope, U-CMAD3 Olympus camera). Metaphases (30) at approxi-
mately the 400 band level were analysed and karyotyped using an auto-
mated cytogenetic imaging system (MetaSystems Gmbh, Germany).
3.6. Dystrophin mutation analyses by multiple ligation probe ampliﬁcation
(MLPA)
Genomic DNAwas extracted from iPSCs using theQIAampDNAMini
Kit (Qiagen) according to manufacturer's instructions. The MLPA reac-
tion was performed to detect all 79 exons of dystrophin gene using
the SALSA MLPA probe sets P034 and P035 (MRC Holland), following
the manufacturer's instructions. The ampliﬁed products were run on
the ABI PRISM 3130 genetic analyser (Applied Biosystems) and the ob-
tained data were analysed using Coffalyser software (MRC Holland).
DNA extracted from iPSCs obtained from a healthy individual's dermal
ﬁbroblast-derived iPSCs were used as controls and included in the run.
3.7. Dystrophin expression in iPSC cardiomyocytes
Differentiation of CCMi001DMD-A-3, Δ49, Δ50 along the
cardiomyogenic lineagewasperformed following amonolayer smallmol-
ecule-based directed differentiation protocol (Lian et al. 2013). Following
7 days of sustained beating (differentiation day 16), cardiomyocyteswereprocessed for the determination of dystrophin and gapdh protein expres-
sion by western immunoblot analysis. All antibody details are listed in
Table 2.
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